01:26:41,686 graphrag.config.read_dotenv INFO Loading pipeline .env file
01:26:41,699 graphrag.index.cli INFO using default configuration: {
    "llm": {
        "api_key": "REDACTED, length 56",
        "type": "openai_chat",
        "model": "llama3-8b-8192",
        "max_tokens": 3000,
        "request_timeout": 300.0,
        "api_base": "https://api.groq.com/openai/v1",
        "api_version": null,
        "proxy": null,
        "cognitive_services_endpoint": null,
        "deployment_name": null,
        "model_supports_json": true,
        "tokens_per_minute": 0,
        "requests_per_minute": 0,
        "max_retries": 5,
        "max_retry_wait": 20.0,
        "sleep_on_rate_limit_recommendation": true,
        "concurrent_requests": 5
    },
    "parallelization": {
        "stagger": 0.5,
        "num_threads": 50
    },
    "async_mode": "threaded",
    "root_dir": ".",
    "reporting": {
        "type": "file",
        "base_dir": "output/${timestamp}/reports",
        "storage_account_blob_url": null
    },
    "storage": {
        "type": "file",
        "base_dir": "output/${timestamp}/artifacts",
        "storage_account_blob_url": null
    },
    "cache": {
        "type": "file",
        "base_dir": "cache",
        "storage_account_blob_url": null
    },
    "input": {
        "type": "file",
        "file_type": "text",
        "base_dir": "input",
        "storage_account_blob_url": null,
        "encoding": "utf-8",
        "file_pattern": ".*\\.txt$",
        "file_filter": null,
        "source_column": null,
        "timestamp_column": null,
        "timestamp_format": null,
        "text_column": "text",
        "title_column": null,
        "document_attribute_columns": []
    },
    "embed_graph": {
        "enabled": false,
        "num_walks": 10,
        "walk_length": 40,
        "window_size": 2,
        "iterations": 3,
        "random_seed": 597832,
        "strategy": null
    },
    "embeddings": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_embedding",
            "model": "nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf",
            "max_tokens": 4000,
            "request_timeout": 180.0,
            "api_base": "http://localhost:1234/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": null,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 10,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "batch_size": 16,
        "batch_max_tokens": 8191,
        "target": "required",
        "skip": [],
        "vector_store": null,
        "strategy": null
    },
    "chunks": {
        "size": 300,
        "overlap": 100,
        "group_by_columns": [
            "id"
        ],
        "strategy": null
    },
    "snapshots": {
        "graphml": false,
        "raw_entities": false,
        "top_level_nodes": false
    },
    "entity_extraction": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": "prompts/entity_extraction.txt",
        "entity_types": [
            "organization",
            "person",
            "geo",
            "event"
        ],
        "max_gleanings": 0,
        "strategy": null
    },
    "summarize_descriptions": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": "prompts/summarize_descriptions.txt",
        "max_length": 500,
        "strategy": null
    },
    "community_reports": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": null,
        "max_length": 2000,
        "max_input_length": 8000,
        "strategy": null
    },
    "claim_extraction": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "enabled": false,
        "prompt": "prompts/claim_extraction.txt",
        "description": "Any claims or facts that could be relevant to information discovery.",
        "max_gleanings": 0,
        "strategy": null
    },
    "cluster_graph": {
        "max_cluster_size": 10,
        "strategy": null
    },
    "umap": {
        "enabled": false
    },
    "local_search": {
        "text_unit_prop": 0.5,
        "community_prop": 0.1,
        "conversation_history_max_turns": 5,
        "top_k_entities": 10,
        "top_k_relationships": 10,
        "max_tokens": 12000,
        "llm_max_tokens": 2000
    },
    "global_search": {
        "max_tokens": 3000,
        "data_max_tokens": 12000,
        "map_max_tokens": 1000,
        "reduce_max_tokens": 2000,
        "concurrency": 32
    },
    "encoding_model": "cl100k_base",
    "skip_workflows": []
}
01:26:41,705 graphrag.index.create_pipeline_config INFO skipping workflows 
01:26:41,708 graphrag.index.run INFO Running pipeline
01:26:41,708 graphrag.index.storage.file_pipeline_storage INFO Creating file storage at output\20240715-012641\artifacts
01:26:41,710 graphrag.index.input.load_input INFO loading input from root_dir=input
01:26:41,710 graphrag.index.input.load_input INFO using file storage for input
01:26:41,714 graphrag.index.storage.file_pipeline_storage INFO search input for files matching .*\.txt$
01:26:41,715 graphrag.index.input.text INFO found text files from input, found [('breast_cancer.txt', {})]
01:26:41,731 graphrag.index.workflows.load INFO Workflow Run Order: ['create_base_text_units', 'create_base_extracted_entities', 'create_summarized_entities', 'create_base_entity_graph', 'create_final_entities', 'create_final_nodes', 'create_final_communities', 'join_text_units_to_entity_ids', 'create_final_relationships', 'join_text_units_to_relationship_ids', 'create_final_community_reports', 'create_final_text_units', 'create_base_documents', 'create_final_documents']
01:26:41,732 graphrag.index.run INFO Final # of rows loaded: 1
01:26:42,35 graphrag.index.run INFO Running workflow: create_base_text_units...
01:26:42,38 graphrag.index.run INFO dependencies for create_base_text_units: []
01:26:42,49 datashaper.workflow.workflow INFO executing verb orderby
01:26:42,68 datashaper.workflow.workflow INFO executing verb zip
01:26:42,79 datashaper.workflow.workflow INFO executing verb aggregate_override
01:26:42,104 datashaper.workflow.workflow INFO executing verb chunk
01:26:42,802 datashaper.workflow.workflow INFO executing verb select
01:26:42,832 datashaper.workflow.workflow INFO executing verb unroll
01:26:42,886 datashaper.workflow.workflow INFO executing verb rename
01:26:42,912 datashaper.workflow.workflow INFO executing verb genid
01:26:42,943 datashaper.workflow.workflow INFO executing verb unzip
01:26:42,976 datashaper.workflow.workflow INFO executing verb copy
01:26:43,4 datashaper.workflow.workflow INFO executing verb filter
01:26:43,70 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_text_units.parquet
01:26:43,830 graphrag.index.run INFO Running workflow: create_base_extracted_entities...
01:26:43,834 graphrag.index.run INFO dependencies for create_base_extracted_entities: ['create_base_text_units']
01:26:43,836 graphrag.index.run INFO read table from storage: create_base_text_units.parquet
01:26:44,54 datashaper.workflow.workflow INFO executing verb entity_extract
01:26:44,138 graphrag.llm.openai.create_openai_client INFO Creating OpenAI client base_url=https://api.groq.com/openai/v1
01:26:44,213 graphrag.index.llm.load_llm INFO create TPM/RPM limiter for llama3-8b-8192: TPM=0, RPM=0
01:26:44,214 graphrag.index.llm.load_llm INFO create concurrency limiter for llama3-8b-8192: 5
01:26:45,258 datashaper.workflow.workflow INFO executing verb merge_graphs
01:26:45,675 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_extracted_entities.parquet
01:26:46,90 graphrag.index.run INFO Running workflow: create_summarized_entities...
01:26:46,90 graphrag.index.run INFO dependencies for create_summarized_entities: ['create_base_extracted_entities']
01:26:46,95 graphrag.index.run INFO read table from storage: create_base_extracted_entities.parquet
01:26:46,218 datashaper.workflow.workflow INFO executing verb summarize_descriptions
01:26:48,377 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_summarized_entities.parquet
01:26:48,698 graphrag.index.run INFO Running workflow: create_base_entity_graph...
01:26:48,698 graphrag.index.run INFO dependencies for create_base_entity_graph: ['create_summarized_entities']
01:26:48,699 graphrag.index.run INFO read table from storage: create_summarized_entities.parquet
01:26:48,750 datashaper.workflow.workflow INFO executing verb cluster_graph
01:26:49,335 datashaper.workflow.workflow INFO executing verb select
01:26:49,342 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_entity_graph.parquet
01:26:49,682 graphrag.index.run INFO Running workflow: create_final_entities...
01:26:49,682 graphrag.index.run INFO dependencies for create_final_entities: ['create_base_entity_graph']
01:26:49,683 graphrag.index.run INFO read table from storage: create_base_entity_graph.parquet
01:26:49,750 datashaper.workflow.workflow INFO executing verb unpack_graph
01:26:49,968 datashaper.workflow.workflow INFO executing verb rename
01:26:49,982 datashaper.workflow.workflow INFO executing verb select
01:26:49,998 datashaper.workflow.workflow INFO executing verb dedupe
01:26:50,44 datashaper.workflow.workflow INFO executing verb rename
01:26:50,59 datashaper.workflow.workflow INFO executing verb filter
01:26:50,129 datashaper.workflow.workflow INFO executing verb text_split
01:26:50,176 datashaper.workflow.workflow INFO executing verb drop
01:26:50,197 datashaper.workflow.workflow INFO executing verb merge
01:26:50,583 datashaper.workflow.workflow INFO executing verb text_embed
01:26:50,590 graphrag.llm.openai.create_openai_client INFO Creating OpenAI client base_url=http://localhost:1234/v1
01:26:50,608 graphrag.index.llm.load_llm INFO create TPM/RPM limiter for nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf: TPM=0, RPM=0
01:26:50,608 graphrag.index.llm.load_llm INFO create concurrency limiter for nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf: 5
01:26:50,749 graphrag.index.verbs.text.embed.strategies.openai INFO embedding 969 inputs via 969 snippets using 61 batches. max_batch_size=16, max_tokens=8191
01:29:51,466 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
01:29:51,469 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"STAGE IV IBC":"Stage IV IBC is a stage of breast cancer with a 5-year OS rate of 25-33%."', '"DE NOVO STAGE IV DISEASE":"De novo stage IV disease is a stage of breast cancer with a median OS time of 2.27 years for IBC."', '"STAGE III DISEASE":"Stage III disease is a stage of breast cancer with a median OS of 4.75 years for IBC."', '"AMERICAN JOINT COMMITTEE ON CANCER":Here is a comprehensive summary of the data:\n\nThe American Joint Committee on Cancer (AJCC) is a medical organization that plays a significant role in the diagnosis and treatment of breast cancer. Specifically, the AJCC provides diagnostic criteria for Inflammatory Breast Cancer (IBC) and has developed a staging system for breast cancer. This staging system helps healthcare professionals to accurately assess the extent of breast cancer and determine the most effective course of treatment for each patient.', '"BREAST SKIN":"breast skin is a location affected by IBC, characterized by diffuse erythema and edema."', '"LYMPHATICS":"lymphatics are a location affected by IBC, characterized by tumor emboli within dermal lymphatics."', '"TUMOR EMBOLI":Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.', '"LYMPH NODE INVOLVEMENT":"lymph node involvement refers to the presence of cancer cells in the lymph nodes."', '"DIAGNOSIS":"diagnosis is the process of identifying IBC based on clinical diagnosis and biopsy specimens."', '"LYMPHEDEMA":"Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics."', '"HR+/HER2-NEGATIVE":"HR+/HER2-negative is a subtype of IBC characterized by the presence of hormone receptors and absence of HER2 receptors."', '"HR+/HER2-POSITIVE":"HR+/HER2-positive is a subtype of IBC characterized by the presence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-POSITIVE":"HR-negative/HER2-positive is a subtype of IBC characterized by the absence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-NEGATIVE":"HR-negative/HER2-negative is a subtype of IBC characterized by the absence of hormone receptors and absence of HER2 receptors."', '"BONE METASTASIS":"Bone metastasis is a common site of metastasis in all subtypes of IBC."', '"LIVER METASTASIS":"Liver metastasis has frequently occurred in the HER2+ subtype of IBC."']}
01:29:51,471 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
01:29:51,473 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"NEOADJUVANT SYSTEMIC THERAPY":"Neoadjuvant Systemic Therapy is a type of treatment for breast cancer that is used before surgery."', '"EVENT-FREE SURVIVAL":Here is a comprehensive summary of the data:\n\n"Event-Free Survival" refers to the measure of the time from treatment initiation to the occurrence of a disease-related event, such as disease progression or death. It is a key metric used to evaluate the effectiveness of treatment in preventing or delaying the onset of a disease-related event.', '"OVERALL SURVIVAL":"Overall Survival is a measure of the time from treatment to death from any cause."', '"PCR":Here is a comprehensive summary of the data:\n\nPCR, also known as pathological complete response, is a measure of treatment effectiveness in breast cancer. It refers to the absence of residual cancer cells after treatment, including neoadjuvant therapy. PCR is a promising outcome and a term used in studies to describe it. The rate of pathological complete response, or PCR, is a percentage of patients who achieve this outcome, and it is often used to evaluate the effectiveness of cancer treatment, particularly in patients with inflammatory breast cancer (IBC).', '"OS":Here is a comprehensive summary of the data:\n\n"OS" refers to overall survival, a measure of the length of time patients with breast cancer survive after treatment. It is a clinical outcome in breast cancer and a term used in studies to describe overall survival. OS is a measure of overall survival rate, which is a measure of treatment effectiveness. It is also a measure of the efficacy of trastuzumab addition in patients with HER2+/HR- subtype. In the context of inflammatory breast cancer (IBC), OS refers to the overall survival rate. Overall, OS stands for overall survival, which is a measure of cancer treatment effectiveness.\n\nI hope this summary meets your requirements! Let me know if you have any further requests.', '"HR":Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.', '"HER2":Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.', '"MEDICAL ONCOLOGIST":"Medical oncologist is a type of doctor who specializes in cancer treatment."', '"SURGEON":"Surgeon is a type of doctor who specializes in surgical procedures."', '"PATHOLOGIST":"Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells."', '"DIAGNOSTIC RADIOLOGIST":"Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests."', '"RADIATION ONCOLOGIST":Here is a comprehensive summary of the data:\n\nA radiation oncologist is a medical professional who specializes in the treatment of cancer using radiation therapy. They are a type of doctor who focuses on the use of radiation therapy to combat cancer.\n\nNote: I combined the two descriptions to create a single, coherent summary that includes all the relevant information.', '"HR/HER2+ IBC"', '"CLINICAL TRIALS":Here is a comprehensive summary of the data:\n\nClinical trials are studies that evaluate the effectiveness, safety, and efficacy of various treatments for breast cancer, including new systemic regimens in patients with Inflammatory Breast Cancer (IBC). These studies investigate the potential role of new treatments in patients with breast cancer, with a focus on evaluating their ability to effectively treat the disease while ensuring their safety for patients.', '"TEAM":"Team is a group of medical professionals working together to improve the survival of IBC."', '"CRISTOFANILLI ET AL.":Here is a comprehensive summary of the data:\n\nCristofanilli et al. are researchers who conducted a study on the effectiveness of paclitaxel in breast cancer treatment.\n\nThis summary provides a brief overview of the entity, Cristofanilli et al., and their research focus on the effectiveness of paclitaxel in breast cancer treatment.']}
01:29:51,476 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
01:32:52,628 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"STAGE IV IBC":"Stage IV IBC is a stage of breast cancer with a 5-year OS rate of 25-33%."', '"DE NOVO STAGE IV DISEASE":"De novo stage IV disease is a stage of breast cancer with a median OS time of 2.27 years for IBC."', '"STAGE III DISEASE":"Stage III disease is a stage of breast cancer with a median OS of 4.75 years for IBC."', '"AMERICAN JOINT COMMITTEE ON CANCER":Here is a comprehensive summary of the data:\n\nThe American Joint Committee on Cancer (AJCC) is a medical organization that plays a significant role in the diagnosis and treatment of breast cancer. Specifically, the AJCC provides diagnostic criteria for Inflammatory Breast Cancer (IBC) and has developed a staging system for breast cancer. This staging system helps healthcare professionals to accurately assess the extent of breast cancer and determine the most effective course of treatment for each patient.', '"BREAST SKIN":"breast skin is a location affected by IBC, characterized by diffuse erythema and edema."', '"LYMPHATICS":"lymphatics are a location affected by IBC, characterized by tumor emboli within dermal lymphatics."', '"TUMOR EMBOLI":Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.', '"LYMPH NODE INVOLVEMENT":"lymph node involvement refers to the presence of cancer cells in the lymph nodes."', '"DIAGNOSIS":"diagnosis is the process of identifying IBC based on clinical diagnosis and biopsy specimens."', '"LYMPHEDEMA":"Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics."', '"HR+/HER2-NEGATIVE":"HR+/HER2-negative is a subtype of IBC characterized by the presence of hormone receptors and absence of HER2 receptors."', '"HR+/HER2-POSITIVE":"HR+/HER2-positive is a subtype of IBC characterized by the presence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-POSITIVE":"HR-negative/HER2-positive is a subtype of IBC characterized by the absence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-NEGATIVE":"HR-negative/HER2-negative is a subtype of IBC characterized by the absence of hormone receptors and absence of HER2 receptors."', '"BONE METASTASIS":"Bone metastasis is a common site of metastasis in all subtypes of IBC."', '"LIVER METASTASIS":"Liver metastasis has frequently occurred in the HER2+ subtype of IBC."']}
01:32:52,798 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
01:32:53,0 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
01:32:53,109 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"NEOADJUVANT SYSTEMIC THERAPY":"Neoadjuvant Systemic Therapy is a type of treatment for breast cancer that is used before surgery."', '"EVENT-FREE SURVIVAL":Here is a comprehensive summary of the data:\n\n"Event-Free Survival" refers to the measure of the time from treatment initiation to the occurrence of a disease-related event, such as disease progression or death. It is a key metric used to evaluate the effectiveness of treatment in preventing or delaying the onset of a disease-related event.', '"OVERALL SURVIVAL":"Overall Survival is a measure of the time from treatment to death from any cause."', '"PCR":Here is a comprehensive summary of the data:\n\nPCR, also known as pathological complete response, is a measure of treatment effectiveness in breast cancer. It refers to the absence of residual cancer cells after treatment, including neoadjuvant therapy. PCR is a promising outcome and a term used in studies to describe it. The rate of pathological complete response, or PCR, is a percentage of patients who achieve this outcome, and it is often used to evaluate the effectiveness of cancer treatment, particularly in patients with inflammatory breast cancer (IBC).', '"OS":Here is a comprehensive summary of the data:\n\n"OS" refers to overall survival, a measure of the length of time patients with breast cancer survive after treatment. It is a clinical outcome in breast cancer and a term used in studies to describe overall survival. OS is a measure of overall survival rate, which is a measure of treatment effectiveness. It is also a measure of the efficacy of trastuzumab addition in patients with HER2+/HR- subtype. In the context of inflammatory breast cancer (IBC), OS refers to the overall survival rate. Overall, OS stands for overall survival, which is a measure of cancer treatment effectiveness.\n\nI hope this summary meets your requirements! Let me know if you have any further requests.', '"HR":Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.', '"HER2":Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.', '"MEDICAL ONCOLOGIST":"Medical oncologist is a type of doctor who specializes in cancer treatment."', '"SURGEON":"Surgeon is a type of doctor who specializes in surgical procedures."', '"PATHOLOGIST":"Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells."', '"DIAGNOSTIC RADIOLOGIST":"Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests."', '"RADIATION ONCOLOGIST":Here is a comprehensive summary of the data:\n\nA radiation oncologist is a medical professional who specializes in the treatment of cancer using radiation therapy. They are a type of doctor who focuses on the use of radiation therapy to combat cancer.\n\nNote: I combined the two descriptions to create a single, coherent summary that includes all the relevant information.', '"HR/HER2+ IBC"', '"CLINICAL TRIALS":Here is a comprehensive summary of the data:\n\nClinical trials are studies that evaluate the effectiveness, safety, and efficacy of various treatments for breast cancer, including new systemic regimens in patients with Inflammatory Breast Cancer (IBC). These studies investigate the potential role of new treatments in patients with breast cancer, with a focus on evaluating their ability to effectively treat the disease while ensuring their safety for patients.', '"TEAM":"Team is a group of medical professionals working together to improve the survival of IBC."', '"CRISTOFANILLI ET AL.":Here is a comprehensive summary of the data:\n\nCristofanilli et al. are researchers who conducted a study on the effectiveness of paclitaxel in breast cancer treatment.\n\nThis summary provides a brief overview of the entity, Cristofanilli et al., and their research focus on the effectiveness of paclitaxel in breast cancer treatment.']}
01:32:53,114 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
01:32:56,898 httpx INFO HTTP Request: POST http://localhost:1234/v1/embeddings "HTTP/1.1 200 OK"
01:32:56,980 graphrag.llm.base.rate_limiting_llm INFO perf - llm.embedding "Process" with 2 retries took 0.875. input_tokens=1095, output_tokens=0
01:32:57,858 httpx INFO HTTP Request: POST http://localhost:1234/v1/embeddings "HTTP/1.1 200 OK"
01:32:57,935 graphrag.llm.base.rate_limiting_llm INFO perf - llm.embedding "Process" with 0 retries took 0.9529999999795109. input_tokens=1236, output_tokens=0
01:32:58,679 httpx INFO HTTP Request: POST http://localhost:1234/v1/embeddings "HTTP/1.1 200 OK"
01:32:58,743 graphrag.llm.base.rate_limiting_llm INFO perf - llm.embedding "Process" with 0 retries took 0.8130000000237487. input_tokens=918, output_tokens=0
01:35:54,821 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"STAGE IV IBC":"Stage IV IBC is a stage of breast cancer with a 5-year OS rate of 25-33%."', '"DE NOVO STAGE IV DISEASE":"De novo stage IV disease is a stage of breast cancer with a median OS time of 2.27 years for IBC."', '"STAGE III DISEASE":"Stage III disease is a stage of breast cancer with a median OS of 4.75 years for IBC."', '"AMERICAN JOINT COMMITTEE ON CANCER":Here is a comprehensive summary of the data:\n\nThe American Joint Committee on Cancer (AJCC) is a medical organization that plays a significant role in the diagnosis and treatment of breast cancer. Specifically, the AJCC provides diagnostic criteria for Inflammatory Breast Cancer (IBC) and has developed a staging system for breast cancer. This staging system helps healthcare professionals to accurately assess the extent of breast cancer and determine the most effective course of treatment for each patient.', '"BREAST SKIN":"breast skin is a location affected by IBC, characterized by diffuse erythema and edema."', '"LYMPHATICS":"lymphatics are a location affected by IBC, characterized by tumor emboli within dermal lymphatics."', '"TUMOR EMBOLI":Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.', '"LYMPH NODE INVOLVEMENT":"lymph node involvement refers to the presence of cancer cells in the lymph nodes."', '"DIAGNOSIS":"diagnosis is the process of identifying IBC based on clinical diagnosis and biopsy specimens."', '"LYMPHEDEMA":"Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics."', '"HR+/HER2-NEGATIVE":"HR+/HER2-negative is a subtype of IBC characterized by the presence of hormone receptors and absence of HER2 receptors."', '"HR+/HER2-POSITIVE":"HR+/HER2-positive is a subtype of IBC characterized by the presence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-POSITIVE":"HR-negative/HER2-positive is a subtype of IBC characterized by the absence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-NEGATIVE":"HR-negative/HER2-negative is a subtype of IBC characterized by the absence of hormone receptors and absence of HER2 receptors."', '"BONE METASTASIS":"Bone metastasis is a common site of metastasis in all subtypes of IBC."', '"LIVER METASTASIS":"Liver metastasis has frequently occurred in the HER2+ subtype of IBC."']}
01:35:54,910 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
01:35:55,654 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
01:35:55,748 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
01:38:58,966 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"STAGE IV IBC":"Stage IV IBC is a stage of breast cancer with a 5-year OS rate of 25-33%."', '"DE NOVO STAGE IV DISEASE":"De novo stage IV disease is a stage of breast cancer with a median OS time of 2.27 years for IBC."', '"STAGE III DISEASE":"Stage III disease is a stage of breast cancer with a median OS of 4.75 years for IBC."', '"AMERICAN JOINT COMMITTEE ON CANCER":Here is a comprehensive summary of the data:\n\nThe American Joint Committee on Cancer (AJCC) is a medical organization that plays a significant role in the diagnosis and treatment of breast cancer. Specifically, the AJCC provides diagnostic criteria for Inflammatory Breast Cancer (IBC) and has developed a staging system for breast cancer. This staging system helps healthcare professionals to accurately assess the extent of breast cancer and determine the most effective course of treatment for each patient.', '"BREAST SKIN":"breast skin is a location affected by IBC, characterized by diffuse erythema and edema."', '"LYMPHATICS":"lymphatics are a location affected by IBC, characterized by tumor emboli within dermal lymphatics."', '"TUMOR EMBOLI":Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.', '"LYMPH NODE INVOLVEMENT":"lymph node involvement refers to the presence of cancer cells in the lymph nodes."', '"DIAGNOSIS":"diagnosis is the process of identifying IBC based on clinical diagnosis and biopsy specimens."', '"LYMPHEDEMA":"Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics."', '"HR+/HER2-NEGATIVE":"HR+/HER2-negative is a subtype of IBC characterized by the presence of hormone receptors and absence of HER2 receptors."', '"HR+/HER2-POSITIVE":"HR+/HER2-positive is a subtype of IBC characterized by the presence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-POSITIVE":"HR-negative/HER2-positive is a subtype of IBC characterized by the absence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-NEGATIVE":"HR-negative/HER2-negative is a subtype of IBC characterized by the absence of hormone receptors and absence of HER2 receptors."', '"BONE METASTASIS":"Bone metastasis is a common site of metastasis in all subtypes of IBC."', '"LIVER METASTASIS":"Liver metastasis has frequently occurred in the HER2+ subtype of IBC."']}
01:38:59,871 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
01:39:00,657 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
01:39:00,664 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
08:15:18,109 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"STAGE IV IBC":"Stage IV IBC is a stage of breast cancer with a 5-year OS rate of 25-33%."', '"DE NOVO STAGE IV DISEASE":"De novo stage IV disease is a stage of breast cancer with a median OS time of 2.27 years for IBC."', '"STAGE III DISEASE":"Stage III disease is a stage of breast cancer with a median OS of 4.75 years for IBC."', '"AMERICAN JOINT COMMITTEE ON CANCER":Here is a comprehensive summary of the data:\n\nThe American Joint Committee on Cancer (AJCC) is a medical organization that plays a significant role in the diagnosis and treatment of breast cancer. Specifically, the AJCC provides diagnostic criteria for Inflammatory Breast Cancer (IBC) and has developed a staging system for breast cancer. This staging system helps healthcare professionals to accurately assess the extent of breast cancer and determine the most effective course of treatment for each patient.', '"BREAST SKIN":"breast skin is a location affected by IBC, characterized by diffuse erythema and edema."', '"LYMPHATICS":"lymphatics are a location affected by IBC, characterized by tumor emboli within dermal lymphatics."', '"TUMOR EMBOLI":Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.', '"LYMPH NODE INVOLVEMENT":"lymph node involvement refers to the presence of cancer cells in the lymph nodes."', '"DIAGNOSIS":"diagnosis is the process of identifying IBC based on clinical diagnosis and biopsy specimens."', '"LYMPHEDEMA":"Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics."', '"HR+/HER2-NEGATIVE":"HR+/HER2-negative is a subtype of IBC characterized by the presence of hormone receptors and absence of HER2 receptors."', '"HR+/HER2-POSITIVE":"HR+/HER2-positive is a subtype of IBC characterized by the presence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-POSITIVE":"HR-negative/HER2-positive is a subtype of IBC characterized by the absence of hormone receptors and presence of HER2 receptors."', '"HR-NEGATIVE/HER2-NEGATIVE":"HR-negative/HER2-negative is a subtype of IBC characterized by the absence of hormone receptors and absence of HER2 receptors."', '"BONE METASTASIS":"Bone metastasis is a common site of metastasis in all subtypes of IBC."', '"LIVER METASTASIS":"Liver metastasis has frequently occurred in the HER2+ subtype of IBC."']}
08:15:18,119 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
08:15:18,124 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
08:15:18,131 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
08:15:35,891 httpx INFO HTTP Request: POST http://localhost:1234/v1/embeddings "HTTP/1.1 200 OK"
08:15:36,77 graphrag.llm.base.rate_limiting_llm INFO perf - llm.embedding "Process" with 5 retries took 0.9849999999860302. input_tokens=569, output_tokens=0
08:18:34,541 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
08:18:34,573 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
08:18:34,581 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
08:21:54,671 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
08:21:54,679 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
08:21:54,686 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
08:25:14,743 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
08:25:14,749 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
08:25:14,759 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
08:28:34,807 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
08:28:34,814 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
08:28:34,822 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
08:31:54,840 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"IBC":Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.', '"HER2+":"HER2+ refers to human epidermal growth factor receptor 2-positive breast cancer subtype."', '"HR-":"HR- refers to hormone receptor-negative breast cancer subtype."', '"HER2-":Here is a comprehensive summary of the data:\n\n"HER2-" refers to a subtype of breast cancer that lacks the human epidermal growth factor receptor 2 (HER2) protein. This type of breast cancer is characterized by the absence of the HER2 protein, which is a key receptor involved in cell growth and division.', '"TRIPLE-NEGATIVE":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE refers to a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2. Specifically, it is characterized by negative receptors for estrogen, progesterone, and HER2, making it a distinct category of breast cancer being studied in the provided articles.', '"BONE":"Bone is a common metastasis site for breast cancer."', '"LIVER":"Liver is a metastasis site for HER2+ breast cancer subtype."', '"LUNG":"Lung is a metastasis site for triple-negative breast cancer subtype."', '"PLEURAL EFFUSION":"Pleural Effusion is a metastasis site for IBC (inflammatory breast cancer)."', '"BRAIN":"Brain is a metastasis site for breast cancer, with a higher rate for triple-negative subtype."', '"SEERS":"SEERs is a database used to track breast cancer outcomes."', '"INSTITUTE":Here is a comprehensive summary of the data:\n\nThe "INSTITUTE" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.', '"HR+"', '"TRIPLE-NEGATIVE IBC":Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.', '"HER2+ IBC":Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.', '"PATHOLOGICAL COMPLETE RESPONSE":Here is a comprehensive summary of the data:\n\nThe entity "Pathological Complete Response" is a medical concept related to cancer treatment. Specifically, it is a prognostic marker of neoadjuvant therapy for breast cancer, including inflammatory breast cancer (IBC).']}
08:31:54,858 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"HER2+ EARLY BREAST CANCER":"HER2+ early breast cancer is a condition being researched and treated in the NeoALTTO trial."', '"PHER2":"pHER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHER3":"pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER2":"phosphorylated HER2 is a concept or marker that is associated with response to lapatinib treatment."', '"PHOSPHORYLATED HER3":"phosphorylated HER3 is a concept or marker that is associated with response to lapatinib treatment."', '"CO-EXPRESSION":"co-expression of phosphorylated HER2 and pHER3 is a concept or marker that is associated with response to lapatinib treatment."', '"DOSE REDUCTION":"dose reduction is an event that may occur due to toxicity of treatment."', '"DISCONTINUATION OF TREATMENT":"discontinuation of treatment is an event that may occur due to toxicity of treatment."', '"TOXICITY":"toxicity is a concept or marker that is associated with the side effects of treatment."', '"RESPONSE RATE":Here is a comprehensive summary of the data:\n\nThe "RESPONSE RATE" refers to the percentage of participants or patients who respond to a treatment. It is a concept or marker that is associated with the effectiveness of treatment. In other words, response rate measures the proportion of individuals who exhibit a positive outcome or improvement in response to a particular treatment or intervention.', '"PREDICTIVE MARKER":"predictive marker is a concept or marker that is associated with the likelihood of response to treatment."', '"PCR RATE":Here is a comprehensive summary of the data:\n\nThe "PCR Rate" is a concept or marker that measures the effectiveness of treatment, specifically in the context of breast cancer and inflammatory breast cancer (IBC). It is an endpoint in clinical trials for IBC and refers to the percentage of patients who achieve a pathologic complete response (pCR) to treatment. In other words, the pCR rate is the rate of patients who achieve a complete response to treatment, as determined by a pathologic examination of the breast tissue. This rate is used to assess the effectiveness of treatments for breast cancer and IBC, providing valuable information for healthcare professionals and researchers.', '"EARLY BREAST CANCER":"early breast cancer is an event or condition being researched and treated."', '"T-DM1":Here is a comprehensive summary of the data:\n\n"T-DM1" is a medication used in the treatment of breast cancer, specifically in the treatment of HER2+ breast cancer. It is a type of antibody-drug conjugate, which is a targeted therapy that combines an antibody with a chemotherapy drug to deliver the treatment directly to the cancer cells. T-DM1 is used to treat HER2+ breast cancer, including HER2+ inflammatory breast cancer (IBC) cases without a pathologic complete response (pCR).', '"KRISTINE TRIAL":Here is a comprehensive summary of the data:\n\nThe KRISTINE trial is a randomized phase 3 trial that evaluated the efficacy of neoadjuvant treatment with T-DM1 plus pertuzumab in patients with HER2+ breast cancer. Specifically, the trial aimed to assess the effectiveness of this combination therapy in treating HER2+ breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions to provide a single, coherent summary.', '"TCHP REGIMEN":Here is a comprehensive summary of the data:\n\nThe "TCHP REGIMEN" is a chemotherapy regimen used to treat breast cancer. Specifically, it is a combination therapy that includes trastuzumab and pertuzumab, two targeted therapies that work together to combat the disease.']}
08:31:54,864 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': ['"SADIE SALEEM":"Sadie Saleem is an author of a review on systemic treatment for inflammatory breast cancer."', '"BORA LIM":Here is a comprehensive summary of the data:\n\nBora Lim is a translational investigator at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is dedicated to discovering novel therapeutic strategies to halt or treat aggressive breast cancer. Additionally, Bora Lim has authored a review on systemic treatment for inflammatory breast cancer, providing valuable insights into this specific area of research.', '"VICENTE VALERO":Here is a comprehensive summary of the data:\n\nVicente Valero is a researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, where he is involved in breast cancer research. Specifically, he has authored a review on systemic treatment for inflammatory breast cancer, showcasing his expertise in the field.', '"NAOTO T. UENO":Here is a comprehensive summary of the data:\n\nNaoto T. Ueno is a professor of medicine at The University of Texas MD Anderson Cancer Center. He specializes in the fields of inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), and metastatic breast cancer. Additionally, Naoto T. Ueno is an author of a review on systemic treatment for inflammatory breast cancer.', '"THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER":Here is a comprehensive summary of the data:\n\nThe University of Texas MD Anderson Cancer Center is a cancer research and treatment center located in Houston, Texas, USA. It provides treatment for various types of cancer and is a leading institution in the field of cancer research and care. The center is home to a team of renowned experts, including Vicente Valero and Naoto T. Ueno, who are actively involved in cancer research and treatment. Additionally, Sudpreeda Chainitikun is currently working at the center. Naoto T. Ueno also works as a professor of medicine at the institution. The authors of the text are affiliated with the University of Texas MD Anderson Cancer Center, indicating a strong connection to the institution\'s research and academic activities.', '"MORGAN WELCH INFLAMMATORY BREAST CANCER RESEARCH PROGRAM AND CLINIC":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic is a research program and clinic at The University of Texas MD Anderson Cancer Center."', '"INFLAMMATORY BREAST CANCER":Here is a comprehensive summary of the data:\n\nInflammatory Breast Cancer is a rare and aggressive type of breast cancer characterized by rapid onset and aggressive progression. It is a specific type of breast cancer that is studied in various research papers, articles, and texts, and is the subject of various studies and consensus statements. This type of breast cancer is characterized by rapid growth and spread of cancer cells, and is often treated with high-dose chemotherapy with autologous hematopoietic stem-cell support.', '"SYSTEMIC THERAPY":"Systemic Therapy refers to the treatment of Inflammatory Breast Cancer."', '"TRIMODALITY TREATMENT":Here is a comprehensive summary of the data:\n\nThe "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC) that involves a composite of systemic treatment, surgery, and radiation. This treatment approach is specifically designed to address the unique characteristics and challenges of IBC, a rare and aggressive form of breast cancer.\n\nNote: I resolved the contradiction by assuming that the entity "Trimodality Treatment" is a treatment approach for Inflammatory Breast Cancer (IBC), as both descriptions mention IBC.', '"BREAST CANCER":Here is a comprehensive summary of the data provided:\n\nBreast Cancer is a type of cancer that affects the breast tissue, with a risk of recurrence and potential survival benefits from extended adjuvant endocrine therapy. It is a disease that is being studied in various research papers and is the focus of multiple studies and research papers. Breast Cancer is a subtype of Inflammatory Breast Cancer and is treated with various systemic treatments, including Pazopanib and Lapatinib. The disease has improved treatment outcomes over the past two decades and is being researched and treated using various technologies and treatments.\n\nBreast Cancer is a type of cancer that affects women and is treated with various therapies, including high-dose chemotherapy with autologous hematopoietic stem-cell support. The disease is discussed in the text, including Inflammatory Breast Cancer (IBC) and non-IBC, and is being treated in the NeoSphere trial with T-DM1 and other therapies. Breast Cancer is a medical condition that was studied in several papers and is the subject of multiple studies.\n\nOverall, Breast Cancer is a type of cancer that requires treatment and is being extensively researched and treated using various therapies and technologies.', '"SUDPREEDA CHAINITIKUN":Here is a comprehensive summary of the data:\n\nSudpreeda Chainitikun is a medical oncologist who has completed a fellowship in medical oncology.', '"SYSTEMIC TREATMENT":Here is a comprehensive summary of the data:\n\nSYSTEMIC TREATMENT refers to the use of medications to treat cancer, specifically breast cancer. It involves the administration of chemotherapy and targeted therapies to combat the disease. This type of treatment is a common approach for treating Inflammatory Breast Cancer (IBC), as well as other types of breast cancer.\n\nNote: I have resolved any potential contradictions by combining the information from each description to provide a clear and concise summary.', '"PATHOLOGIC COMPLETE RESPONSE":"Pathologic Complete Response refers to the absence of cancer cells in the breast tissue after treatment."', '"SURVIVAL OUTCOMES":Here is a comprehensive summary of the data:\n\nSurvival Outcomes refer to the length of time a patient with Inflammatory Breast Cancer (IBC) survives after treatment. The use of systemic treatments for breast cancer has led to improved survival outcomes for patients with IBC.', '"PREDICTIVE MARKERS":"Predictive Markers are biological indicators that can predict the effectiveness of treatment for IBC."', '"ADVERSE EVENTS":Here is a comprehensive summary of the data:\n\nADVERSE EVENTS refer to the negative side effects that can occur during treatment for breast cancer, specifically for Inflammatory Breast Cancer (IBC). These adverse events are serious side effects that can occur as a result of treatment for breast cancer, including IBC.']}
08:31:54,903 datashaper.workflow.workflow ERROR Error executing verb "text_embed" in create_final_entities: Request timed out.
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 69, in map_httpcore_exceptions
    yield
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 373, in handle_async_request
    resp = await self._pool.handle_async_request(req)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 216, in handle_async_request
    raise exc from None
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 196, in handle_async_request
    response = await connection.handle_async_request(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 101, in handle_async_request
    return await self._connection.handle_async_request(request)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 143, in handle_async_request
    raise exc
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 113, in handle_async_request
    ) = await self._receive_response_headers(**kwargs)
        ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 186, in _receive_response_headers
    event = await self._receive_event(timeout=timeout)
            ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 224, in _receive_event
    data = await self._network_stream.read(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_backends\anyio.py", line 32, in read
    with map_exceptions(exc_map):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_exceptions.py", line 14, in map_exceptions
    raise to_exc(exc) from exc
httpcore.ReadTimeout

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1558, in _request
    response = await self._client.send(
               ^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1661, in send
    response = await self._send_handling_auth(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1689, in _send_handling_auth
    response = await self._send_handling_redirects(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1726, in _send_handling_redirects
    response = await self._send_single_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1763, in _send_single_request
    response = await transport.handle_async_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 372, in handle_async_request
    with map_httpcore_exceptions():
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 86, in map_httpcore_exceptions
    raise mapped_exc(message) from exc
httpx.ReadTimeout

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\datashaper\workflow\workflow.py", line 415, in _execute_verb
    result = await result
             ^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 105, in text_embed
    return await _text_embed_in_memory(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 130, in _text_embed_in_memory
    result = await strategy_exec(texts, callbacks, cache, strategy_args)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 61, in run
    embeddings = await _execute(llm, text_batches, ticker, semaphore)
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 105, in _execute
    results = await asyncio.gather(*futures)
              ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 339, in __wakeup
    future.result()
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 267, in __step
    result = coro.send(None)
             ^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 99, in embed
    chunk_embeddings = await llm(chunk)
                       ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 49, in __call__
    return await self._invoke(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_embeddings_llm.py", line 36, in _execute_llm
    embedding = await self.client.embeddings.create(
                ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\embeddings.py", line 215, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1577, in _request
    raise APITimeoutError(request=request) from err
openai.APITimeoutError: Request timed out.
08:31:54,999 graphrag.index.reporting.file_workflow_callbacks INFO Error executing verb "text_embed" in create_final_entities: Request timed out. details=None
08:31:55,31 graphrag.index.run ERROR error running workflow create_final_entities
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 69, in map_httpcore_exceptions
    yield
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 373, in handle_async_request
    resp = await self._pool.handle_async_request(req)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 216, in handle_async_request
    raise exc from None
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection_pool.py", line 196, in handle_async_request
    response = await connection.handle_async_request(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\connection.py", line 101, in handle_async_request
    return await self._connection.handle_async_request(request)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 143, in handle_async_request
    raise exc
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 113, in handle_async_request
    ) = await self._receive_response_headers(**kwargs)
        ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 186, in _receive_response_headers
    event = await self._receive_event(timeout=timeout)
            ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_async\http11.py", line 224, in _receive_event
    data = await self._network_stream.read(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_backends\anyio.py", line 32, in read
    with map_exceptions(exc_map):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpcore\_exceptions.py", line 14, in map_exceptions
    raise to_exc(exc) from exc
httpcore.ReadTimeout

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1558, in _request
    response = await self._client.send(
               ^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1661, in send
    response = await self._send_handling_auth(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1689, in _send_handling_auth
    response = await self._send_handling_redirects(
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1726, in _send_handling_redirects
    response = await self._send_single_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_client.py", line 1763, in _send_single_request
    response = await transport.handle_async_request(request)
               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 372, in handle_async_request
    with map_httpcore_exceptions():
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\contextlib.py", line 155, in __exit__
    self.gen.throw(typ, value, traceback)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\httpx\_transports\default.py", line 86, in map_httpcore_exceptions
    raise mapped_exc(message) from exc
httpx.ReadTimeout

The above exception was the direct cause of the following exception:

Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\run.py", line 323, in run_pipeline
    result = await workflow.run(context, callbacks)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\datashaper\workflow\workflow.py", line 369, in run
    timing = await self._execute_verb(node, context, callbacks)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\datashaper\workflow\workflow.py", line 415, in _execute_verb
    result = await result
             ^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 105, in text_embed
    return await _text_embed_in_memory(
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\text_embed.py", line 130, in _text_embed_in_memory
    result = await strategy_exec(texts, callbacks, cache, strategy_args)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 61, in run
    embeddings = await _execute(llm, text_batches, ticker, semaphore)
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 105, in _execute
    results = await asyncio.gather(*futures)
              ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 339, in __wakeup
    future.result()
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\asyncio\tasks.py", line 267, in __step
    result = coro.send(None)
             ^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\verbs\text\embed\strategies\openai.py", line 99, in embed
    chunk_embeddings = await llm(chunk)
                       ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 49, in __call__
    return await self._invoke(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_embeddings_llm.py", line 36, in _execute_llm
    embedding = await self.client.embeddings.create(
                ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\embeddings.py", line 215, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1577, in _request
    raise APITimeoutError(request=request) from err
openai.APITimeoutError: Request timed out.
08:31:55,42 graphrag.index.reporting.file_workflow_callbacks INFO Error running pipeline! details=None
